Chronic Kidney Disease Drugs Market, By Drug Class, By Route of Administration, By Indication, By Distribution Channel, By Geography

Description

Global chronic kidney disease drugs market is estimated to be valued at USD 15.10 Billion in 2024 and is expected to reach USD 21.55 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2024:	US$ 15.10 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2024 to 2031 CAGR:	5.20%	2031 Value Projection:	US$ 21.55 Bn

Figure. Chronic Kidney Disease Drugs Market Share (%), By Region 2024

Chronic Kidney Disease Drugs Market - IMG1

Global chronic kidney disease drugs market h growth is driven by rising prevalence of kidney disorders worldwide. Chronic kidney disease (CKD) refers to the gradual loss of kidney function over time. If left untreated, CKD can eventually lead to kidney failure or end-stage renal disease. Some of the common causes of CKD include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Growing geriatric populations and increasing lifestyle diseases can lead to increased prevalence of CKD. The chronic kidney disease drugs aim to slow down the progression of the disease, treat complications, and help maintain overall kidney health. Renin-angiotensin system inhibitors, calcium channel blockers, erythropoiesis-stimulating agents, and diuretics are some of the major drug classes used for managing chronic kidney diseases.

Market Dynamics:

Global chronic kidney disease drugs market growth is driven by rising prevalence of diabetes and hypertension as both are significant risk factors for CKD. According to the data published by the International Diabetes Federation, nearly 537 million adults lived with diabetes in 2021 across the globe. This number is anticipated to rise to 643 million by 2030 and 783 million by 2045. High blood pressure, or hypertension, is also a major culprit for CKD cases. Favorable government initiatives to spread awareness about early diagnosis and treatment of kidney diseases can drive the market growth. However, stringent regulations for new drug approval and the risk of severe side effects associated with long-term therapy can hamper the market growth. The development of combinational and targeted therapies presents lucrative opportunities for manufacturers in the chronic kidney disease drugs industry.

Key features of the study:

This report provides in-depth analysis of the global chronic kidney disease drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi, Keryx Biopharmaceuticals, Kissei Pharmaceutical Co. Ltd., AstraZeneca plc, Teva Pharmaceutical Industries Ltd.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market

Detailed Segmentation-

By Drug Class
- ACE Inhibitors
- Angiotensin Receptor Blockers (ARBs)
- B-Blockers
- Calcium Channel Blockers
- Loop Diuretics
- Erythropoiesis-Stimulating Agents (ESAs)
- Phosphate Binders
- Others
By Route of Administration:
- Oral
- Parenteral
By Indication
- Diabetic Nephropathy
- Glomerulonephritis
- Hypertensive Nephropathy
- Polycystic Kidney Disease
- Other Indications
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Key Players Insights
- AstraZeneca
- Amgen Inc.
- Hoffmann-La Roche Ltd.
- Pfizer, Inc.
- Sanofi
- GlaxoSmithKline plc (GSK)
- AbbVie Inc.
- Keryx Biopharmaceuticals, Inc.
- Kissei Pharmaceutical Co., Ltd.
- Regeneron Pharmaceuticals, Inc.
- Bayer AG
- Reata Pharmaceuticals, Inc.
- Ardelyx, Inc.
- Boehringer Ingelheim International GmbH
- Novo Nordisk A/S
- Novartis AG
- Johnson & Johnson
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited
- Akebia Therapeutics, Inc.

Product Code: CMI1713

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Chronic Kidney Disease Drugs Market, By Drug Class
- Global Chronic Kidney Disease Drugs Market, By Route of Administration
- Global Chronic Kidney Disease Drugs Market, By Indication
- Global Chronic Kidney Disease Drugs Market, By Distribution Channel
- Global Chronic Kidney Disease Drugs Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
ACE Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Angiotensin Receptor Blockers (ARBs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
B-Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Calcium Channel Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Loop Diuretics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Erythropoiesis-Stimulating Agents (ESAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Phosphate Binders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

5. Global Chronic Kidney Disease Drugs Market, By Route of Administration, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Parentral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Chronic Kidney Disease Drugs Market, By Indication, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Diabetic Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Glomerulonephritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Hypertensive Nephropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Polycystic Kidney Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Other Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2019-2031, (USD Bn)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2020 - 2031
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Chronic Kidney Disease Drugs Market, By Region, 2019 - 2031, (USD Bn)

Introduction
- Market Share (%) Analysis, 2024,2027 & 2031, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2019 - 2031, (USD Bn)
- Regional Trends
  - North America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country, 2019 - 2031, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
  - Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2019 - 2031, V (USD Bn)
- Market Size and Forecast, By Indication, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031, (USD Bn)
- Market Size and Forecast, By Country/Region, 2019 - 2031, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

9. Competitive Landscape

AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Amgen Inc.
F. Hoffmann-La Roche Ltd.
Pfizer, Inc.
Sanofi
GlaxoSmithKline plc (GSK)
AbbVie Inc.
Keryx Biopharmaceuticals, Inc.
Kissei Pharmaceutical Co., Ltd.
Regeneron Pharmaceuticals, Inc.
Bayer AG
Reata Pharmaceuticals, Inc.
Ardelyx, Inc.
Boehringer Ingelheim International GmbH
Novo Nordisk A/S
Novartis AG
Johnson & Johnson
Astellas Pharma Inc.
Takeda Pharmaceutical Company Limited
Akebia Therapeutics, Inc.

10. Analyst Recommendations

Wheel of Fortune
Analyst View
Coherent Opportunity Map

11. References and Research Methodology

References
Research Methodology
About us